13th edition

Format
HYBRID

December 3rd & 4th, 2024

IN-PERSON | LILLE, FR

December 11th& 12th 2024

ONLINE MEETINGS

Seed funds crossing borders: How far and how fast is the early-stage investment market in biotech globalising?

Seed funds crossing borders: How far and how fast is the early-stage investment market in biotech globalising?

The early-stage investment actors can be seen as traditionally geographically anchored, but now seed and Series A investors tend to invest in more diverse geographic areas. Where does the money come from? How far is this evolution towards more global funds going? How fast is it going in the investment community? Will it make the investors more willing to take risks, will it change the risk landscape? Isn’t there an ill-balance today between the geographical origin of investment capabilities and the areas that are crawling with projects needing equity investment?

Lisa Urquhart

Editor
United Kingdom
Evaluate Vantage

Stephan Lensky

Chief Operating and Chief Business Officer
China
EpimAb Biotherapeutics

Jemila Houacine

Associate
Switzerland
Medicxi

Mirko Scherer

Managing Partner and CEO
China
TVM Capital China Limited

Zishan Haroon

Chairman and General Partner
USA
Julz Co
Scroll to Top
  • No products in the cart.